GFM
ZBIO icon

GF Fund Management’s Zenas BioPharma ZBIO Stock Holding History

GF Fund Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.9K Sell
1,138
-67
-6% -$1.33K ﹤0.01% 450
2026
Q1 		$23.6K Buy
1,205
+151
+14% +$3.39K ﹤0.01% 484
2025
Q4 		$38.3K Buy
+1,054
New +$34.7K ﹤0.01% 430

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

GF Fund Management's ZBIO Position: Q2 2026 in Review

GF Fund Management reduced its Zenas BioPharma (ZBIO) stake by 5.6% in Q2 2026, selling an estimated $1.33K and leaving 1,138 shares worth $28.9K. The position accounts for ﹤0.01% of the portfolio, ranked #450.

GF Fund Management first reported a position in ZBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $38.3K in Q4 2025. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • GF Fund Management held 1,138 shares of Zenas BioPharma worth $28.9K as of Q2 2026.
  • GF Fund Management sold 67 Zenas BioPharma shares in Q2 2026, an estimated $1.33K.
  • Zenas BioPharma made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #450 holding.
  • GF Fund Management first reported a position in Zenas BioPharma in Q4 2025 and has held it in 3 quarters since.
  • GF Fund Management's Zenas BioPharma position peaked at $38.3K in Q4 2025.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.